This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Biotech Stock Live Chat

Stocks in this article: CLSN AMAG BPAX AMRN HGSI VRUS VVUS

BOSTON ( TheStreet) -- Welcome to September's Biotech Stock Live Chat. The floor is yours.

I'm here for the next 90 minutes to answer your biotech investing questions and hopefully spark some interactive debate on the hot biotech topics of the day. This chat only works if you participate, so please keep the questions and comments flowing in the box below.

One hot topic I'd like to hash out today is new drug launches. Are there identifiable factors that can help predict whether a new drug launch will be a success or failure? Is there something about Vertex Pharmaceuticals (VRTX) and its Hep C drug Incivek, for example, which could have told us in advance that the drug would beat early investor expectations?

Conversely, what signals were present with Somaxon Pharmaceuticals (SOMX) or Human Genome Sciences (HGSI) that could have helped us predict trouble with their respective new drug launches?

The investment bank Leerink Swann took a deep dive into this issue that yielded some interesting conclusions and potentially helpful ways for investors to think about drug launches. I'll share some of these findings today during the Live Chat.

The topic is important as investors look ahead to potential new drug launches from companies like NPS Pharmaceuticals (NPSP), Alexza Pharmaceuticals (ALXA), InterMune (ITMN), Biogen Idec (BIIB), Corcept Therapeutics (CORT), Incyte (INCY), Affymax (AFFY) and others.

Trending biotech and drugs stocks on Twitter these days include BioSante Pharmaceuticals (BPAX), Celsion (CLSN), Pharmasset (VRUS), Adventrx Pharmaceuticals (ANX) and Amarin (AMRN). Let's discuss.

Will the merger between Amag Pharmaceuticals (AMAG) and Allos Therapeutics (ALTH) close? The shareholder vote is scheduled for Oct. 21. I have some thoughts on the subject.

And obesity drug stocks are back in the news again after Vivus (VVUS) announced this morning that it will resubmit Qnexa to the FDA in October. The FDA is said to be planning another advisory panel for the first quarter.

Let's talk about these stocks today, or any other biotech investing subjects that pique your interest. Please join me live.

--Written by Adam Feuerstein in Boston.

>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to

>To submit a news tip, send an email to:

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs